Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Recruiting Not applicable Interventional

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

NCT02604277
View directory record Official record
Conditions
Depression, Alcoholism, Drug Abuse
Interventions
Interpersonal and Social Rhythm Therapy (ISRT), Bipolar-Specific Cognitive Behavioral Therapy (CBT), Mindfulness-Based Stress Reduction (MBSR), Psycho-education & Understanding Bipolar Medications Therapy
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 64 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Not yet recruiting Not applicable Interventional

Light Utilization COX-Inhibitory Device Therapy for Infant Cardiac Arrest (LUTICA Study). The LUCID Device is Used in the Treatment of Ischemic Brain Reperfusion Injury Caused by Cardiac Arrest in Pediatric Patients.

NCT07556939
View directory record Official record
Conditions
Reperfusion Injury, Post Cardiac Arrest Brain Injury
Interventions
LUTICIA - Light Utilization COX-Inhibitory Device)
Device
Lead sponsor
Mitovation, Inc
Industry
Eligibility
48 Hours to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Massage: Neuroimaging and Correlates of Response - 1-week Study

NCT07190313
View directory record Official record
Conditions
Healthy Participants
Interventions
Swedish Massage Therapy, Light Touch Control
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional

A Randomized Trial: Changing Behavior in Post-Angioplasty Patients

NCT00248846
View directory record Official record
Conditions
Angioplasty Patients
Interventions
Intervention Group
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of GLR2007 for Advanced Solid Tumors

NCT04444427
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Glioblastoma Multiforme
Interventions
GLR2007
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Lafayette, Indiana • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Water Hydration to Prevent Post-Vaccination Presyncope

NCT02353390
View directory record Official record
Conditions
Presyncope, Syncope
Interventions
Oral Water Hydration
Other
Lead sponsor
Duke University
Other
Eligibility
11 Years to 21 Years
Enrollment
1,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 20, 2026, 5:30 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Fresh Truck Pilot to Reduce Food Insecurity in a Medicaid ACO

NCT04017624
View directory record Official record
Conditions
Food Insecurity
Interventions
Fresh Truck with stipend, THRIVE screening and referral
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Not applicable Interventional

tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia

NCT05866003
View directory record Official record
Conditions
Stroke, Upper Extremity Paresis, Hemiplegia
Interventions
Active conventional tDCS montage plus CCFES, Active unconventional tDCS montage plus CCFES, Sham tDCS plus CCFES, CCFES with Occupational Therapy
Device · Behavioral
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

NCT05074810
View directory record Official record
Conditions
Non Small Cell Lung Cancer, KRAS Activating Mutation
Interventions
avutometinib and sotorasib, avutometinib and sotorasib and defactinib
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Boulder, Colorado • Washington D.C., District of Columbia • Arlington Heights, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1 Interventional

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

NCT02892123
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma, c-MET
Interventions
Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Airway Management of Pediatric Patients With Klippel-Feil Syndrome

NCT03741790
View directory record Official record
Conditions
Klippel-Feil Syndrome
Interventions
Ventilation, Intubation
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Not applicable Interventional

Optimizing Phonological Awareness Learning in Prekindergarten and Kindergarten to Improve Later Reading and Spelling

NCT07017010
View directory record Official record
Conditions
Reading Difficulties
Interventions
phonemic awareness intervention (PA), phonological sensitivity + phonemic awareness intervention (PSPA), delayed onset phonemic awareness intervention (DPA)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
4 Years to 9 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Tallahassee, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

Milk Thistle Clinical Trial in Pediatric NAFLD

NCT06477146
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan
Drug · Behavioral · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NCT02648724
View directory record Official record
Conditions
Oncology, MET Gene Amplification, NSCLC, MET Gene Mutation, Non Small Cell Lung Cancer
Interventions
Sym015
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 2 Interventional

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

NCT07766187
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Histotripsy, Durvalumab, Biopsy
Device · Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 1 Interventional

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

NCT07027514
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
tolododekin alfa, Cetrelimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Coral Gables, Florida • Jacksonville, Florida • Peoria, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Active, not recruiting Phase 1 Interventional

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738
View directory record Official record
Conditions
Small Cell Lung Carcinoma (SCLC)
Interventions
BI 764532, Topotecan, Single agent chemotherapy
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Not yet recruiting No phase listed Observational

UltraTrac Clinical Pilot Study

NCT07864714
View directory record Official record
Conditions
Hemodynamic Monitoring
Interventions
Noninvasive Hemodynamic Monitoring System
Device
Lead sponsor
AcQumen Medical, Inc.
Industry
Eligibility
0 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Not applicable Interventional

Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

NCT03843814
View directory record Official record
Conditions
Gliosarcoma, Glioma
Interventions
APT MRI
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 20, 2026, 5:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

NO Prevention of COVID-19 for Healthcare Providers

NCT04312243
View directory record Official record
Conditions
Coronavirus Infections, Healthcare Associated Infection
Interventions
Inhaled nitric oxide gas
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Completed Not applicable Interventional

Feasibility of a Behavioral Activation Trial

NCT02992158
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
behavioral activation, treatment-as-usual
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 20, 2026, 5:30 PM EDT
Recruiting Phase 1 Interventional

Effect of Insulin Lowering on Lipogenesis

NCT07403604
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 5:30 PM EDT
Withdrawn Phase 1 Interventional

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

NCT07073183
View directory record Official record
Conditions
Squamous NSCLC
Interventions
CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg
Biological
Lead sponsor
CureVac
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Fairfax, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 5:30 PM EDT